Building on its success in establishing a strong pharmaceutical core, Novartis entered a period of continuous strategic transformation, marked by significant portfolio adjustments, acquisitions, and divestments designed to adapt to a dynamically evolving healthcare landscape. This proactive approach was necessitated by several overarching industry trends, including increasing pressure on drug pricing from payers and governments, the impending "patent cliff" for several blockbuster drugs across the industry, and the rising cost and complexity of pharmaceutical research and development. The company systematically evaluated its various business units to ensure alignment with its long-term vision of becoming a focused leader in innovative medicines, particularly those addressing high unmet medical needs. This strategic re-evaluation led to several pivotal decisions that profoundly reshaped the company's structure and direction, aiming to optimize its capital allocation and enhance its competitive posture.
One of the most significant shifts involved the expansion and subsequent re-assessment of its eye care business. In 2010, Novartis completed the acquisition of Alcon, Inc., a global leader in eye care products, for approximately $51.6 billion. This monumental transaction, at the time one of the largest in pharmaceutical history, transformed Novartis's presence in the ophthalmic sector. Alcon brought a diverse portfolio encompassing surgical devices and equipment (e.g., for cataract and vitreoretinal surgery), contact lenses, lens care solutions, and over-the-counter eye drops. This diversified eye care division integrated well with Novartis's existing pharmaceutical ophthalmic pipeline, including Lucentis (ranibizumab), a significant treatment for wet age-related macular degeneration. The strategic rationale articulated by leadership was to create a comprehensive, vertically integrated eye care franchise, capitalizing on the demographic trend of an aging global population and the increasing incidence of age-related eye diseases, positioning Novartis as a dominant player in a growing healthcare segment with projected long-term growth.
However, the ensuing years brought new and intensified challenges that forced a further strategic pivot. The pharmaceutical industry faced increased generic competition, particularly with the patent expiration of Diovan (valsartan), Novartis's former top-selling antihypertensive drug, in the U.S. in 2012 and Europe in 2011. Diovan had generated peak annual revenues exceeding $6 billion, and its loss created a substantial revenue gap that necessitated aggressive portfolio restructuring. Simultaneously, global drug pricing pressure intensified, with major markets demanding greater value for money from pharmaceutical innovations. These factors prompted Novartis to undertake a substantial portfolio transformation between 2014 and 2015. This period saw the company engage in a series of high-value asset swaps and divestments aimed at sharpening its focus. Notable transactions included the sale of its vaccines business (excluding flu) to GlaxoSmithKline (GSK) for up to $7.1 billion and the simultaneous acquisition of GSK's oncology assets for $16 billion. This latter move significantly bolstered Novartis's cancer portfolio with new compounds and market share in key areas. Concurrently, Novartis divested its animal health division to Eli Lilly for approximately $5.4 billion and formed a consumer healthcare joint venture with GSK, effectively streamlining its operations around core innovative pharmaceuticals and eye care, moving away from more diversified, lower-margin segments.
Internal documents and public statements from leadership indicated a clear intent to concentrate resources on high-growth, high-margin therapeutic areas, particularly oncology, immunology, and neuroscience. These fields were experiencing rapid scientific advancements, including breakthroughs in immuno-oncology, gene editing, and targeted therapies, promising significant potential for new innovative medicines. Leveraging its global generics division, Sandoz, for broad market access remained a key pillar of the strategy, providing a strong platform in established markets and expanding presence in emerging economies through affordable medicines. This strategic pivot required robust internal adjustments, including changes in organizational structure, significant reinvestment in research and development, and redeployment of resources to support the refined therapeutic focus. The company actively pursued research in advanced therapies, recognizing their potential to revolutionize medicine. This included substantial investments in cell and gene therapies, such as Kymriah (tisagenlecleucel), an early CAR-T cell therapy approved in 2017, and Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy approved in 2019, signalling a bold move into groundbreaking scientific territories.
Despite these strategic maneuvers, challenges persisted. The pharmaceutical industry faced heightened regulatory scrutiny, particularly regarding data integrity and promotional practices. This led to some high-profile legal and ethical issues, including multi-million dollar settlements related to allegations of illegal marketing and bribery practices in various regions, which required significant management attention and internal reforms. These periods of difficulty, openly addressed by the company, underscored the complexities of operating in a highly regulated global industry and prompted further reinforcement of compliance and governance structures, with a renewed emphasis on ethical conduct and transparency. Furthermore, the generics business, Sandoz, began to face increased pricing pressure in various markets, particularly in the United States, due to heightened competition, consolidation among generic manufacturers, and pressure from major pharmacy benefit managers. This environment, characterized by downward pricing spirals, necessitated a re-evaluation of Sandoz's long-term strategic fit and value contribution within the broader Novartis group.
By the late 2010s, Novartis initiated another major structural shift, culminating in the spin-off of Alcon as a standalone company in April 2019. The decision to divest Alcon, which had been acquired for $51.6 billion less than a decade earlier and valued at approximately $25 billion at the time of its spin-off, reflected a significant evolution in Novartis's overarching corporate strategy. The rationale, as articulated by company leadership, was to unlock shareholder value by allowing both Novartis (focused on innovative medicines) and Alcon (focused on eye care devices and surgical products) to pursue independent growth strategies tailored to their respective industries and market dynamics. Novartis aimed to become a "pure-play" innovative medicines company, concentrating its capital and R&D efforts exclusively on high-value, patent-protected pharmaceuticals and advanced therapies. The spin-off was executed through a dividend of Alcon shares to Novartis shareholders, effectively creating two distinct, publicly traded entities. This substantial restructuring fundamentally redefined the scope and focus of Novartis, orienting it almost exclusively towards the discovery, development, and commercialization of patented pharmaceuticals and advanced therapies, divesting from diversified healthcare segments to maximize its potential for innovation and shareholder returns in a rapidly evolving biopharmaceutical landscape, setting the stage for its subsequent evolution.